Cellid, a developer of virus vector Covid-19 vaccine candidate, AdCLD-CoV19-1, said it has joined the COVAX Marketplace that allocates raw materials for vaccines.
The innovative market coordinated by COVAX provides suppliers with a platform to allocate or reallocate unused materials for vaccines, mobilizing potential surplus stock from manufacturers with non-vaccine activities.
The Korean company said it would cooperate in developing a Covid-19 vaccine and accelerating global production by playing a role in ensuring that the vaccine is distributed fairly and equitably through COVAX Facility.
The COVAX Marketplace was established to solve the short-term bottleneck by facilitating access to raw and subsidiary materials necessary to produce the Covid-19 vaccines. COVAX Facility aims to accelerate the global production of Covid-19 vaccine doses by matching existing suppliers of critical inputs with vaccine manufacturers who urgently need them to produce vaccines for fair distribution through COVAX.
The marketplace provides the Coalition for Epidemic Preparedness Innovations (CEPI) with a platform to safely input demand and inventory required by vaccine manufacturers or raw materials suppliers.
CEPI will identify offers and match requests according to priorities based on certain criteria, including whether a manufacturer has a COVAX advance purchase agreement or dose volumes and delivery timing, to guarantee that the highly complex and cross-border reliant vaccine distribution system will continue to provide for COVAX.
As a participant in the COVAX Marketplace, Cellid will request or provide raw materials for manufacturing vaccines. In addition, the company plans to cooperate globally to develop and produce Covid-19 vaccines, including its AdCLD-CoV19-1 vaccine candidate.
Recently, Cellid completed administrating AdCLD-CoV19-1 to patients in phase 1 clinical trial. In October, the company plans to apply for phase 2 and 3 clinical trial designs to the Ministry of Food and Drug Safety.
“We intend to use our resources and technologies to contribute to providing sufficient Covid-19 vaccines to underprivileged groups around the world through the COVAX Marketplace,” Cellid CEO Kang Chang-yul said.
In June, Cellid changed the adenoviral vector of its Covid-19 vaccine candidate AdCLD-CoV19 and applied for additional phase 1 and 2 clinical trials to the Ministry of Food and Drug Safety. Besides, the company has developed adenovirus vector vaccines, as AstraZeneca and Janssen did, a company official said.